MINDACT/Microarray In Node negative Disease

[1] MINDACT/Microarray In Node negative Disease may Avoid ChemoTherapy Trial/EORTC Protocol 10041 ? BIG 3-04)
[2] Piccart M, Rutgers E, Van? t Veer L, Slaets L, Delaloge S, Viale G, Pierga JY, et al. Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. Abstract: CT039 Presentation Session: Clinical Trials Plenary Session, Monday, April 18, 10:30 a.m.-12:30 p.m. CT, La Nouvelle Orleans Ballroom.